MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), D. Gary Gilliland(Brigham and Women's Hospital), Nicky Duclos(Brigham and Women's Hospital), Benjamin H. Lee(Novartis (United States)), Ifor R. Williams(Emory University), Shinichi Mizuno(Sendai Shakai Hoken Hospital), Koichi Akashi(Kyushu University), R. M. Rowan(Queen's University Belfast), Kenji Deguchi(Brigham and Women's Hospital), David P. Curley(Massachusetts General Hospital), Hirokazu Shigematsu(Dana-Farber Cancer Institute), Sonia M Amaral(Brigham and Women's Hospital)
Cited by 701
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k